[The impact of neuroprotection on brain metabolism during carotid endarterectomy].

Mracek J, Holecková I, Lavicka P, Mork J, Stepánek D, Struncová P, Cervený V

Casopis lekaru ceskych1 Jan 2011Cited by 2 (Europe PMC)

PMID22132616PepBankPUB-22132616

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

01HumanNot a test of Cerebrolysin aloneNon-randomized trialOther
In carotid endarterectomy patients, combined neuroprotection produced higher S100B levels than no neuroprotection.
In plain wordsDuring carotid surgery, the combined neuroprotection regimen produced higher S100B levels than no neuroprotection.
Peptide
Cerebrolysin
Outcome
IncreaseS100B
Study
n = 70
Comparator
No neuroprotection
Analysis
Primary
Outcome group
Neuroprotection · Nervous system and cognition
Measurements
Median S100B
0.117
Neuroprotection
Median S100B
0.088
Control
P value for S100B levels
< 0.0182
Combined neuroprotection versus no neuroprotection during carotid endarterectomy
Source sentences
Summary
In the group with neuroprotection there were significantly higher levels of S100B (median 0.117 vs. 0.088; p < 0.0182), lactate (median 1.92 vs. 1.020; p < 0.0006), glycaemia (median 9.5 vs. 8.2; p < 0.0243), and SvjO2 (median 0.79 vs. 0.65; p < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 35 patients underwent carotid endarterectomy with prophylactic combined neuroprotection (Sendai cocktail: Manitol, Phenhydan, Solumedrol, Tokoferol; Cerebrolysin;
Summary · context
There were 35 patients in the control group who where operated on without any neuroprotection.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2213261603
02HumanNot a test of Cerebrolysin aloneNon-randomized trialOther
In carotid endarterectomy patients, combined neuroprotection produced higher lactate levels than no neuroprotection.
In plain wordsDuring carotid surgery, the combined neuroprotection regimen produced higher lactate levels than no neuroprotection.
Peptide
Cerebrolysin
Outcome
IncreaseLactate
Study
n = 70
Comparator
No neuroprotection
Analysis
Primary
Outcome group
Metabolic pathways and metabolomics · Nervous system and cognition
Measurements
Median lactate
1.92
Neuroprotection
Median lactate
1.02
Control
P value for lactate levels
< 0.0006
Combined neuroprotection versus no neuroprotection during carotid endarterectomy
Source sentences
Summary
In the group with neuroprotection there were significantly higher levels of S100B (median 0.117 vs. 0.088; p < 0.0182), lactate (median 1.92 vs. 1.020; p < 0.0006), glycaemia (median 9.5 vs. 8.2; p < 0.0243), and SvjO2 (median 0.79 vs. 0.65; p < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 35 patients underwent carotid endarterectomy with prophylactic combined neuroprotection (Sendai cocktail: Manitol, Phenhydan, Solumedrol, Tokoferol; Cerebrolysin;
Summary · context
There were 35 patients in the control group who where operated on without any neuroprotection.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2213261604
03HumanNot a test of Cerebrolysin aloneNon-randomized trialOther
In carotid endarterectomy patients, combined neuroprotection produced higher glycaemia than no neuroprotection.
In plain wordsDuring carotid surgery, the combined neuroprotection regimen produced higher blood glucose than no neuroprotection.
Peptide
Cerebrolysin
Outcome
IncreaseGlycaemia
Study
n = 70
Comparator
No neuroprotection
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Measurements
Median glycaemia
9.5
Neuroprotection
Median glycaemia
8.2
Control
p value for glycaemia comparison
< 0.0243
Combined neuroprotection versus no neuroprotection, intraoperative jugular bulb sample before vessel unclamping
Source sentences
Summary
In the group with neuroprotection there were significantly higher levels of S100B (median 0.117 vs. 0.088; p < 0.0182), lactate (median 1.92 vs. 1.020; p < 0.0006), glycaemia (median 9.5 vs. 8.2; p < 0.0243), and SvjO2 (median 0.79 vs. 0.65; p < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 35 patients underwent carotid endarterectomy with prophylactic combined neuroprotection (Sendai cocktail: Manitol, Phenhydan, Solumedrol, Tokoferol; Cerebrolysin;
Summary · context
There were 35 patients in the control group who where operated on without any neuroprotection.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2213261605
04HumanNot a test of Cerebrolysin aloneNon-randomized trialOther
In carotid endarterectomy patients, combined neuroprotection produced higher SvjO2 than no neuroprotection.
In plain wordsDuring carotid surgery, the combined neuroprotection regimen produced higher jugular blood oxygen saturation than no neuroprotection.
Peptide
Cerebrolysin
Outcome
IncreaseJugular bulb oxygen saturation
Study
n = 70
Comparator
No neuroprotection
Analysis
Primary
Outcome group
Metabolic pathways and metabolomics · Nervous system and cognition
Measurements
Median SvjO2
0.79
Neuroprotection
Median SvjO2
0.65
Control
p value for SvjO2 comparison
< 0.0001
Combined neuroprotection versus no neuroprotection, intraoperative jugular bulb sample before vessel unclamping
Source sentences
Summary
In the group with neuroprotection there were significantly higher levels of S100B (median 0.117 vs. 0.088; p < 0.0182), lactate (median 1.92 vs. 1.020; p < 0.0006), glycaemia (median 9.5 vs. 8.2; p < 0.0243), and SvjO2 (median 0.79 vs. 0.65; p < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 35 patients underwent carotid endarterectomy with prophylactic combined neuroprotection (Sendai cocktail: Manitol, Phenhydan, Solumedrol, Tokoferol; Cerebrolysin;
Summary · context
There were 35 patients in the control group who where operated on without any neuroprotection.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2213261606
05HumanNot a test of Cerebrolysin aloneNon-randomized trialEfficacy outcome
In carotid endarterectomy patients, NIHSS did not change in either the combined neuroprotection group or the control group.
In plain wordsAfter carotid surgery, stroke scores did not change in either the combined neuroprotection group or the control group.
Peptide
Cerebrolysin
Outcome
No significant changePostoperative NIHSS
Study
n = 70
Comparator
No neuroprotection
Analysis
Secondary
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Postoperative NIHSS did not change in any patients in either group.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 35 patients underwent carotid endarterectomy with prophylactic combined neuroprotection (Sendai cocktail: Manitol, Phenhydan, Solumedrol, Tokoferol; Cerebrolysin;
Summary · context
There were 35 patients in the control group who where operated on without any neuroprotection.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2213261601
06HumanNot a test of Cerebrolysin aloneNon-randomized trialOther
In carotid endarterectomy patients, no intraoperative shunt was inserted in either study group.
In plain wordsDuring carotid surgery, no shunt was inserted in either the combined neuroprotection group or the control group.
Peptide
Cerebrolysin
Outcome
No significant changeIntraoperative shunt use
Study
n = 70
Comparator
No neuroprotection
Outcome group
Intensive care and hospital outcomes · Nervous system and cognition
Source sentences
Summary
An intraoperative shunt was not inserted in any patients in either group.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 35 patients underwent carotid endarterectomy with prophylactic combined neuroprotection (Sendai cocktail: Manitol, Phenhydan, Solumedrol, Tokoferol; Cerebrolysin;
Summary · context
There were 35 patients in the control group who where operated on without any neuroprotection.
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-2213261602

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.